Scholar Rock Holding Corporation (SRRK)
| Market Cap | 182.86M |
| Revenue (ttm) | 47.30M |
| Net Income (ttm) | -112.08M |
| Shares Out | 35.30M |
| EPS (ttm) | -3.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 157,533 |
| Open | 5.80 |
| Previous Close | 5.99 |
| Day's Range | 5.02 - 5.87 |
| 52-Week Range | 5.02 - 44.95 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 45.29 (+774.3%) |
| Earnings Date | May 12, 2022 |
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-P...
Financial Performance
In 2021, SRRK's revenue was $18.82 million, an increase of 22.16% compared to the previous year's $15.40 million. Losses were -$131.80 million, 52.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for SRRK stock is "Buy." The 12-month stock price forecast is 45.29, which is an increase of 774.32% from the latest price.
News
Scholar Rock Shares Jumps On Updating Strategic Priorities
Scholar Rock Holding Corp (NASDAQ: SRRK) plans to reduce its overall headcount by 25%, and its Chief Medical Officer Yung Chyung will step down by the end of June. "Parting with employees who have dedi...
Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fun...
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 20...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
Scholar Rock Holding Corporation (SRRK) Stock Jumps 9.2%: Will It Continue to Soar?
Scholar Rock Holding Corporation (SRRK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving highe...
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the Am...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced that it is presenting encore data in an e-poster at the American Academy of Neurology (AAN) 2022 Annual Meeting.
Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) C...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces a poster presentation at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 13 - 16.
Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Lags Revenue Estimates
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 6.73% and 4.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for t...
Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q4 Earnings Expected to Decline
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scholar Rock to Present at Cowen's 42nd Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced a presentation at the 2nd Annual TGFβ for Immuno-Oncology Drug Development Summit (January 25-27, 2022).
Scholar Rock Provides Corporate Update and Highlights Priorities for 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients wi...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combinati...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today presented initial clinical data from Part A of its DRAGON Phase 1 proof-of-concept trial at the SITC Annual Meeting.
Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Tops Revenue Estimates
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -20.00% and 24.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead f...
Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
Scholar Rock to Present at Upcoming Healthcare Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q3 Earnings Expected to Decline
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces an e-poster presentation of clinical results from the TOPAZ Phase 2 trial at the 25th World Congress of Neurology (WCN).
Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced a late breaker poster presentation as part of the 50th Child Neurology Society (CNS) Annual Meeting, occurring 9/29 - 10/2.
Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced that the USPTO issued U.S. Patent No. 11,130,803, with projected expiry of May 2040, providing product protection for SRK-181.
Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock is announcing two poster presentations as part of the World Muscle Society (WMS) Virtual Congress taking place September 20-24, 2021.
Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation ...
New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRRK)...